Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced it will report third quarter 2026 financial results on Monday, ...
Travere Therapeutics, Inc. (Nasdaq: TVTX) today presented new biomarker data from the Phase 3 PROTECT Study providing ...
Travere Therapeutics reported durable biomarker data for FILSPARI in IgA nephropathy, but shares fell 4.5% as markets focus ...
Travere Therapeutics presented Phase 3 PROTECT biomarker findings suggesting FILSPARI may modify underlying disease ...
Zacks.com on MSN
Fox (FOXA) Earnings Expected to Grow: Should You Buy?
The market expects Fox (FOXA) to deliver a year-over-year increase in earnings on higher revenues when it reports results for ...
Zacks Investment Research on MSN
AstraZeneca gets accelerated FDA nod for Ultomiris in IgA nephropathy
AstraZeneca AZN announced that the FDA has approved its blockbuster rare disease drug, Ultomiris (ravulizumab), for reducing ...
MedPage Today on MSN
Trio of IgA nephropathy drugs proves mettle in interim analyses
Significant proteinuria reductions reported, but still awaiting eGFR data ...
Detailed price information for Boston Scientific Corp (BSX-N) from The Globe and Mail including charting and trades.
With a late Thursday nod from the FDA to reduce protein levels in the urine of patients with primary immunoglobulin A ...
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.
The new Kidney Care National Plan from the US Department of Health and Human Services focuses on preventing kidney failure, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results